Literature DB >> 21629215

Combination therapy: New treatment paradigm for locally advanced cervical cancer?

Peter G Rose.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21629215     DOI： 10.1038/nrclinonc.2011.85

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study.

Authors:  Alfonso Dueñas-González; Lucely Cetina-Perez; Carlos Lopez-Graniel; Aarón Gonzalez-Enciso; Ernesto Gómez-Gonzalez; Lesbia Rivera-Rubi; Gonzalo Montalvo-Esquivel; David Muñoz-Gonzalez; Juan Robles-Flores; Elisa Vazquez-Govea; Jaime de La Garza; Alejandro Mohar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

2.  Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

Authors:  Alfonso Dueñas-González; Juan J Zarbá; Firuza Patel; Juan C Alcedo; Semir Beslija; Luis Casanova; Pittayapoom Pattaranutaporn; Shahid Hameed; Julie M Blair; Helen Barraclough; Mauro Orlando
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma.

Authors:  P Pattaranutaporn; C Thirapakawong; Y Chansilpa; S Therasakvichya; N Ieumwananontachai; K Thephamongkhol
Journal:  Gynecol Oncol       Date:  2001-06       Impact factor: 5.482

4.  Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.

Authors:  Elizabeth M Swisher; Ron E Swensen; Benjamin Greer; Hisham Tamimi; Barbara A Goff; Rochelle Garcia; Wui-Jin Koh
Journal:  Gynecol Oncol       Date:  2005-12-09       Impact factor: 5.482

5.  Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial.

Authors:  J Umanzor; M Aguiluz; C Pineda; S Andrade; M Erazo; Claudio Flores; Sergio Santillana
Journal:  Gynecol Oncol       Date:  2005-11-08       Impact factor: 5.482

6.  A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma.

Authors:  J J Zarbá; A V Jaremtchuk; P Gonzalez Jazey; M Keropian; R Castagnino; C Mina; G Arroyo
Journal:  Ann Oncol       Date:  2003-08       Impact factor: 32.976

7.  A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.

Authors:  Peter G Rose; Koen Degeest; Scott McMeekin; Nancy Fusco
Journal:  Gynecol Oncol       Date:  2007-08-03       Impact factor: 5.482

8.  Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.

Authors:  Vicharn Lorvidhaya; Imjai Chitapanarux; Supatra Sangruchi; Prasert Lertsanguansinchai; Yongyut Kongthanarat; Saipin Tangkaratt; Ekachai Visetsiri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

9.  Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix.

Authors:  P J Eifel; C Levenback; J T Wharton; M J Oswald
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

10.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:  Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  10 in total
  3 in total

1.  Surface-engineered nanomaterials as X-ray absorbing adjuvant agents for Auger-mediated chemo-radiation.

Authors:  Sang-Min Lee; De-Hao Tsai; Vincent A Hackley; Martin W Brechbiel; Robert F Cook
Journal:  Nanoscale       Date:  2013-06-21       Impact factor: 7.790

2.  Surface Modification of Cisplatin-Complexed Gold Nanoparticles and Its Influence on Colloidal Stability, Drug Loading, and Drug Release.

Authors:  Jiaojie Tan; Tae Joon Cho; De-Hao Tsai; Jingyu Liu; John M Pettibone; Rian You; Vincent A Hackley; Michael R Zachariah
Journal:  Langmuir       Date:  2017-12-18       Impact factor: 3.882

3.  Major clinical research advances in gynecologic cancer in 2011.

Authors:  Dong Hoon Suh; Kidong Kim; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2012-01-09       Impact factor: 4.401
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.